undamentalytics Newsletter
Sign in

Upstream Bio, Inc. income statement

In fiscal 2025, Upstream Bio, Inc. reported revenue of $2.9m, up 20.4% on the year before, operating income of −$160m (a -5618.8% margin) and net income of −$143m, or −$2.66 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2233
Research and development3263137146
General and administrative11172627
Operating income−40−78−160−170
Income tax0000
Net income−21−63−143−157
Diluted EPS−$3.24−$1.40−$2.66−$2.89
Diluted shares (average)12m55m54m54m
EBITDA−40−78−160−170

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: UPB vs XBIOALGS vs UPBDYAI vs UPBUPB vs VTGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Upstream Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Upstream Bio, Inc.